Frezent Joins MSK Therapeutics Accelerator 2025 Cohort to Advance Therapies Targeting Cancer Recurrence.
New York, September 9, 2025 – Frezent Biological Solutions, a New York based oncology therapeutics startup company, focused on eliminating cancer recurrence, is proud to announce its engagement with Memorial Sloan Kettering Cancer Center (MSK) as part of the MSK Therapeutics Accelerator 2025 Cohort.
The MSK Therapeutics Accelerator is a strategic initiative between MSK and biotechnology companies that aims to expedite novel cancer therapeutics through all stages of drug development. It provides industry partners with opportunities to collaborate with MSK’s leading clinical and scientific experts, access to MSK facilities and infrastructure. The Therapeutics Accelerator Cohort program matches company participants with MSK’s investigators to advise on potential collaborations and, if feasible, transition to a formal partnership.
Frezent’s CSO & Co-founder, Dr. Lina Freage and CEO & Co-Founder, Dr. Natasha Shtraizent
“We hope that through partnership with MSK’s world-leading scientists and clinicians, Frezent will be able to design a clinical and regulation strategy that accounts for the challenges in oncology healthcare and is focused on patient benefit and quality of life,” said Dr. Natasha Shtraizent, CEO and Co-founder of Frezent. “Cancer recurrence remains a major unmet need and a major healthcare burden. With MSK’s support, we would be able to advance our novel targeted therapies into IND-enabling studies and deliver impactful solutions for cancer survivors around the world.”
Frezent’s therapeutic approach to preventing cancer relapse is focused on eliminating dormant cancer cells that survive initial treatments and eventually lead to cancer relapse. The company is focused on blocking cancer specific proteins involved in reactivation of dormant cancer cells. Frezent’s platform has already demonstrated in vitro and in vivo proof-of-concept and is preparing for pivotal preclinical and IND enabling studies.
“We are excited to explore collaborations with MSK’s outstanding team to strengthen our strategy and accelerate our efforts on the trajectory towards clinical trials,” said Dr. Lina Freage-Kahn, CSO and Co-founder of Frezent.
Frezent Biological Solutions
Frezent Biological Solutions is a preclinical stage biotechnology company, co-founded by Dr. Natasha Shtraizent and Dr. Lina Freage-Kahn and operating since 2021. The company is addressing the need of cancer patients for a novel therapy that can prevent cancer recurrence. Its therapeutic platform utilizes antibodies and antibody-drug conjugates to block survival of non-dividing dormant cancer cells. Frezent’s portfolio of proprietary antibodies translates into a wide pipeline of patent-protected drug candidates. Frezent’s lead program- a novel target-specific monoclonal antibody demonstrated efficacy and safety in vivo and is now poised to enter IND-enabling studies. Frezent is headquartered in New York, NY. The company is supported by SOSV/ IndieBio NY, NY Ventures and NSF SBIR grant.